439 related articles for article (PubMed ID: 24001888)
1. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
Weinblatt ME; Westhovens R; Mendelsohn AM; Kim L; Lo KH; Sheng S; Noonan L; Lu J; Xu Z; Leu J; Baker D; Bingham CO;
Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Baker D; Ishii Y; Yoshinari T;
Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
[TBL] [Abstract][Full Text] [Related]
3. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
[TBL] [Abstract][Full Text] [Related]
5. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Emery P; Fleischmann RM; Doyle MK; Strusberg I; Durez P; Nash P; Amante E; Churchill M; Park W; Pons-Estel B; Xu W; Xu S; Wu Z; Hsia EC
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
[TBL] [Abstract][Full Text] [Related]
6. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
Emery P; Fleischmann RM; Hsia EC; Xu S; Zhou Y; Baker D
Clin Rheumatol; 2014 Sep; 33(9):1239-46. PubMed ID: 25005327
[TBL] [Abstract][Full Text] [Related]
8. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
[TBL] [Abstract][Full Text] [Related]
9. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
Kavanaugh A; Ritchlin C; Rahman P; Puig L; Gottlieb AB; Li S; Wang Y; Noonan L; Brodmerkel C; Song M; Mendelsohn AM; McInnes IB;
Ann Rheum Dis; 2014 Jun; 73(6):1000-6. PubMed ID: 24553909
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
[TBL] [Abstract][Full Text] [Related]
14. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
[TBL] [Abstract][Full Text] [Related]
15. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
Emery P; Fleischmann R; van der Heijde D; Keystone EC; Genovese MC; Conaghan PG; Hsia EC; Xu W; Baratelle A; Beutler A; Rahman MU
Arthritis Rheum; 2011 May; 63(5):1200-10. PubMed ID: 21305524
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
[TBL] [Abstract][Full Text] [Related]
17. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU
Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
Kavanaugh A; McInnes IB; Mease PJ; Krueger GG; Gladman DD; van der Heijde D; Mudivarthy S; Xu W; Mack M; Xu Z; Beutler A
Ann Rheum Dis; 2013 Nov; 72(11):1777-85. PubMed ID: 23161902
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
Kavanaugh A; McInnes IB; Mease P; Krueger GG; Gladman D; van der Heijde D; Zhou Y; Lu J; Leu JH; Goldstein N; Beutler A
Ann Rheum Dis; 2014 Sep; 73(9):1689-94. PubMed ID: 24748630
[TBL] [Abstract][Full Text] [Related]
20. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
